14M152: Abstracts: RA – Treatment III: Comorbidities and Consequences (2215–2220)

Abstract Moderator(s)

• DH

  Diane Horowitz, MD

  Northwell Health
  Jericho, NY, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose
• 

  Jasvinder Singh, MD, MPH

  University of Alabama at Birmingham
  Birmingham, AL, United States

  Disclosure(s): Adaptimmune Therapeutics: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Adept Field Solutions: Consultant (Ongoing); Amarin: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); American College of Rheumatology: Consultant (Ongoing), Officer or Board Member (Ongoing); Atyu Biopharma: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Charlotte's Web Holdings, Inc.: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Clearview Healthcare Partners: Consultant (Ongoing); Clinical Care Options: Consultant (Ongoing); Crealta/Horizon: Consultant (Ongoing); Enzolytics Inc.: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); FDA Arthritis Advisory Committee: Advisor or Review Panel Member (Ongoing); Fidia: Consultant (Ongoing); Focus Forward: Consultant (Ongoing); GeoVax Labs: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Intuitive Surgical Inc./Philips Electronics North America: food and beverage payment (Ongoing); Jupiter Life Science: Consultant (Ongoing); MedIQ: Consultant (Ongoing); Medisys: Consultant (Ongoing); Medscape: Consultant (Ongoing); Moderna Pharmaceuticals: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); National Institutes of Health: Consultant (Ongoing); Navigant Consulting: Consultant (Ongoing); Outcomes Measures in Rheumatology (OMERACT): Officer or Board Member (Ongoing); Pieris Pharmaceuticals: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); PK Med: Consultant (Ongoing); Practice Point Communications: Consultant (Ongoing); Putnam Associates: Consultant (Ongoing); Schipher: Consultant (Ongoing); Seres Therapeutics: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Simply Speaking: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Spherix: Consultant (Ongoing); Tonix Pharmaceuticals Holding Corp: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); TPT Global Tech: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Trio Health: Consultant (Ongoing); Two Labs Inc.: Consultant (Ongoing); UBM LLC: Consultant (Ongoing); University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis: editor and director (Ongoing); Vaxart Pharmaceuticals: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); Veterans Affairs Rheumatology Field Advisory Board (FAB): Officer or Board Member (Ongoing); Viking: Stock options or bond holdings in a for-profit corporation or self-directed pension plan (Ongoing); WebMD: Consultant (Ongoing); Zimmer Biomet Holdings: Grant/Research Support (Ongoing)

Oral abstract session.

Presentations:

• 3:00 PM – 3:10 PM Eastern Time

  Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis
  

  Presenting Author: Daniel Solomon, MD, MPH – Brigham and Women's Hospital
• 3:10 PM – 3:15 PM Eastern Time

  Q&A
  
• 3:15 PM – 3:25 PM Eastern Time

  JAK Inhibitors and Risk of Cancer
  

  Presenting Author: Jérôme Avouac, MD, PhD – Université de Paris Cité
• 3:25 PM – 3:30 PM Eastern Time

  Q&A
  
• 3:30 PM – 3:40 PM Eastern Time

  Disease Response in Rheumatoid Arthritis Across 4 Biologic Therapies Associates with Improvement in Paraoxonase-1 Activity
  

  Presenting Author: Amir Razmjou, MD – UCLA
• 3:40 PM – 3:45 PM Eastern Time

  Q&A
  
• 3:45 PM – 3:55 PM Eastern Time

  Frailty Is Associated with Serious Infections in Biologic and Targeted-synthetic DMARD Treated Patients with Rheumatoid Arthritis
  

  Presenting Author: Namrata Singh, MD, MSc – University of Washington
• 3:55 PM – 4:00 PM Eastern Time

  Q&A
  
• 4:00 PM – 4:10 PM Eastern Time

  Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis
  

  Presenting Author: Beth I. Wallace, MD, MS – Michigan Medicine, VA Ann Arbor Healthcare System
• 4:10 PM – 4:15 PM Eastern Time

  Q&A
  
• 4:15 PM – 4:25 PM Eastern Time

  Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patients Receiving JAK Inhibitors in South Korea: A Nationwide Population-based Study
  

  Presenting Author: YoungEun Kim, MD – Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
• 4:25 PM – 4:30 PM Eastern Time

  Q&A